MEDIA

Media Inquiries

Investors@OncoSec.com

855-662-6732

Press Releases

VIEW ALL PRESS RELEASES

Video Feed

3D MOA Animation video

✕

OncoSec's VLA 3D MOA Animation

✕

TAVO Demonstration with Dr Algazi

✕

OncoSec at 2020 BIO CEO Panel

✕

Tumor Immunogenicity

✕

IAD Reel

✕

IAD Robert Andtbacka, M.D.

✕

Social Media

Twitter Feed

OncoSec Medical@OncoSec·
22h

Join us next Wednesday as Dr. Michael Atkins, #melanoma survivors Doug Brodman & Susanne Milne, and care partner Nadia Jabri discuss #immunotherapy in the third segment of our "Ask the Expert" Facebook Live series in partnership with @CureMelanoma. https://www.facebook.com/Melanoma.Research.Foundation/

OncoSec Medical@OncoSec·
25 Sep

#DYK that #Metastatic #TNBC is an aggressive type of #breastcancer that has a high recurrence rate within the first 5 years following diagnosis. We encourage you to explore educational resources to better understand #cancer: https://oncosec.com/patients/ #TogetherAgainstCancer

Fox Chase Cancer Center@FoxChaseCancer·
24 Sep

Don't miss "Together Facing #Melanoma" LIVE now. Learn more about treatment options, screening, genetic testing, and the latest research in this field. Watch here: https://bit.ly/3i2nJf4.

OncoSec Medical@OncoSec·
24 Sep

Unable to attend or missed part of yesterday's "Ask the Expert" Facebook Live segment in partnership with @CureMelanoma? Don't sweat! A full recording of the discussion on #melanoma care partners & survivorship can be found here: https://www.facebook.com/Melanoma.Research.Foundation/videos/333648927961723/?extid=lxFAFEmBtLcnXqsp

Featured Articles

Melanoma Research Alliance

From Dermatology to Treatment: Second Opinions, Clinical Trials & becoming Your Own Best Advocate

PharmaVoice

Women of the Week interview with OncoSec’s Chief Clinical Development Officer, Kellie Malloy Foerter

Annals of Oncology

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients

Clinical Cancer Research

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.